Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 1/2 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 83Cyclophosphamide 55Specimen Handling 54Carboplatin 53fludarabine 44Nivolumab 43Magnetic Resonance Spectroscopy 43Gemcitabine 41Biopsy 40venetoclax 33Bevacizumab 33Dexamethasone 31Paclitaxel 29Pemetrexed 27Injections 27Cisplatin 27Docetaxel 26Azacitidine 22atezolizumab 21Rituximab 21Oxaliplatin 21Capecitabine 21Lenalidomide 20Ipilimumab 20Temozolomide 19Fulvestrant 19Cetuximab 19abemaciclib 18Fluorouracil 18Cytarabine 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × poly ICLC × 90 days × Clear all
NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Seqker Biosciences, Inc.

Phase 1/2 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡